Neurobiologic basis of nicotine addiction and psychostimulant abuse: A role for neurotensin?

Psychiatric Clinics of North America

Volumn 28, Issue 3 SPEC. ISS., 2005, Pages 737-751

  Fredrickson, Paul ^a   Boules, Mona ^a   Lin, Siong Chi ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MODAFINIL; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR ANTAGONIST; NICOTINE; NT 69L; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DOPAMINE RELEASE; DRUG ABUSE; DRUG EFFICACY; HUMAN; MENTAL HEALTH; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 23944481933     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2005.05.001     Document Type: Review

References (113)

1. S.E. Hyman, and R.C. Malenka Addiction and the brain: the neurobiology of compulsion and its persistence Nat Rev Neurosci 2 2001 695 703
2. E.J. Nestler, and G.K. Aghajanian Molecular and cellular basis of addiction Science 278 1997 58 63
3. D. Goldman, and C.S. Barr Restoring the addicted brain N Engl J Med 347 2002 843 845
4. C.E. Koop Tobacco addiction: accomplishments and challenges in science, health, and policy Nicotine & Tobacco Research 5 2003 613 619
5. B.M. Tyler-McMahon, M. Boules, and E. Richelson Neurotensin: peptide for the next millennium Regul Pept 93 2000 125 136
6. P.D. Lambert, R. Gross, and C.B. Nemeroff Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system Ann N Y Acad Sci 757 1995 377 389
7. F.B. Jolicoeur, M.A. Gagne, and R. Rivest Atypical neuroleptic-like behavioral effects of neurotensin Brain Res Bull 32 1993 487 491
8. P.W. Glimcher, D.H. Margolin, and A.A. Giovino Neurotensin: a new reward peptide Brain Res 291 1984 119 124
9. No authors listed. Cigarette smoking among adults. MMWR Morb Mortal Wkly Rep 2003;54:509-13.
10. J.M. Murphy, N.J. Horton, and R.R. Monson Cigarette smoking in relation to depression: historical trends from the Stirling County study Am J Psychiatry 160 2003 1663 1669
11. W. Gulbinat, A. Dupont, and A. Jablensky Cancer incidence of schizophrenic patients Br J Psychiatry 161 Suppl 1992 75 83
12. P.B. Mortensen The occurrence of cancer in first admitted schizophrenic patients Schizophr Res 12 1994 185 194
13. J.A. Baldwin Schizophrenia and physical disease Psychol Med 9 1979 611 618
14. M.T. Tsuang, K. Perkins, and J.C. Simpson Physical diseases in schizophrenia and affective disorder J Clin Psychiatry 44 1983 42 46
15. A.E. Harris Physical disease and schizophrenia Schizophr Bull 14 1988 85 96
16. D. Lichtermann, J. Ekelund, and E. Pukkala Incidence of cancer among persons with schizophrenia and their relatives Arch Gen Psychiatry 58 2001 573 578
17. M.T. Tsuang, R.F. Woolson, and J.A. Fleming Premature deaths in schizophrenia and affective disorders Arch Gen Psychiatry 37 1980 979 983
18. P. Allebeck, and B. Wistedt Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register Arch Gen Psychiatry 43 1986 650 653
19. M. Buda, M.T. Tsuang, and J.A. Fleming Causes of death in DSM-III schizophrenics and other psychotics Arch Gen Psychiatry 45 1988 283 285
20. K. Lasser, J.W. Boyd, and S. Woolhandler Smoking and mental illness. A population-based prevalence study JAMA 284 2000 2606 2610
21. G.W. Dalack, D.J. Healy, and J.H. Meador-Woodruff Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings Am J Psychiatry 155 1998 1490 1501
22. L.E. Adler, L.D. Hoffer, and A. Wiser Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am J Psychiatry 150 1993 1856 1861
23. T.P. George, D.M. Ziedonis, and A. Feingold Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia Am J Psychiatry 157 2000 1835 1842
24. R.C. Smith, A. Singh, and M. Infante Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia Neuropsychopharmacology 27 2002 479 497
25. L.E. Adler, E. Pachtman, and R.D. Franks Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia Biol Psychiatry 17 1982 639 654
26. C.S. Tung, J. Grenhoff, and T.H. Svensson Nicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivation Acta Physiol Scand 138 1990 427 428
27. G.G. Nomikos, B. Schilstrom, and B.E. Hildebrand Role of alpha 7 nicotinic receptors in nicotine dependence and implications for psychiatric illness Behav Brain Res 113 2000 97 103
28. J.B. Acri, D.E. Morse, and E.J. Popke Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats Psychopharmacology (Berl) 114 1994 369 374
29. L.E. Adler, A. Olincy, and M. Waldo Schizophrenia, sensory gating, and nicotinic receptors Schizophrenia Bull 24 1998 189 202
30. S. Leonard, C. Breese, and C. Adams Smoking and schizophrenia: abnormal nicotinic receptor expression Eur J Pharmacol 393 2000 237 242
31. J.P. McEvoy, O. Freudenreich, and E.D. Levin Haloperidol increases smoking in patients with schizophrenia Psychopharmacology 119 1995 124 126
32. 2 stimulation and blockade on smoking behavior Exp Clin Psychopharmacol 7 1999 72 78
33. N.H. Caskey, M.E. Jarvik, and W.C. Wirshing Modulating tobacco smoking rates by dopaminergic stimulation and blockade Nicotine Tob Res 4 2002 259 266
34. S. Dawe, C. Gerada, and M.A. Russell Nicotine intake in smokers increases after a single dose of haloperidol Psychopharmacology 117 1995 110 115
35. L.H. Brauer, M.J. Cramblett, and D.A. Paxton Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes Psychopharmacology 159 2001 31 37
36. T.P. George, J.C. Vessicchio, and A. Termine A placebo controlled trial of bupropion for smoking cessation in schizophrenia Biol Psychiatry 52 2002 53 61
37. R.M. Procyshyn, N. Ihsan, and D. Thompson A comparison of smoking behaviours between patients treated with Clozapine and depot neuroleptics Int Clin Psychopharmacol 16 2001 291 294
38. T.P. George, M.J. Sernyak, and D.M. Ziedonis Effects of clozapine on smoking in chronic schizophrenic outpatients J Clin Psychiatry 56 1995 344 346
39. D.R. Combs, and C. Advokat Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia Schizophr Res 46 2000 129 137
40. J.P. McEvoy, O. Freudenreich, and W.H. Wilson Smoking and therapeutic response to clozapine in patients with schizophrenia Biol Psychiatry 46 1999 125 129
41. United Nations Office of Drug Control and Crime Prevention World drug report 2000 2000 Oxford University Press Oxford (UK)
42. Office of National Drug Control Policy Methamphetamine: facts and figures 1998 Office of National Drug Control Policy Washington (DC)
43. W.E. Narrow, D.S. Rae, and L.N. Robins Revised prevalence estimates of mental disorders in the United States Arch Gen Psychiatry 59 2002 115 123
44. J. Grabowski, J. Shearer, and J. Merrill Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence Addict Behav 29 2004 1439 1464
45. M. Silva de Lima, B. Garcia de Oliveira Soares, and A. Alves Pereira Reisser Pharmacological treatment of cocaine dependence: a systematic review Addiction 97 2002 931 949
46. C.A. Dackis, K.G. Lynch, and E. Yu Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study Drug Alcohol Depend 70 2003 29 37
47. L.S. Seiden, K.E. Sabol, and G.A. Ricaurte Amphetamine: effects on catecholamine systems and behavior Annu Rev Pharmacol Toxicol 33 1993 639 677
48. A.E. Fleckenstein, J.W. Gibb, and G.R. Hanson Differential effects of stimulants on monoaminergic transporters Eur J Pharmacol 406 2000 1 13
49. 2 receptors J Pharmacol Exp Ther 291 1999 409 415
50. B.A. Vollm, I.E. de Araujo, and P.J. Cowen Methamphetamine activates reward circuitry in drug naive human subjects Neuropsychopharmacology 29 2004 1715 1722
51. S.H. Ahmed, and G.F. Koob Transition from moderate to excessive drug intake: change in hedonic set point Science 282 1998 298 300
52. T.E. Robinson, and K.C. Berridge The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res Brain Res Rev 18 1993 247 291
53. B.J. Everitt, A. Dickinson, and T.W. Robbins The neuropsychological basis of addictive behaviour Brain Res Brain Res Rev 36 2001 129 138
54. G. Schulteis, A. Markou, and M. Cole Decreased brain reward produced by ethanol withdrawal Proc Natl Acad Sci U S A 92 1995 5880 5884
55. W.J. McBride, J.M. Murphy, and S. Ikemoto Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies Behav Brain Res 101 1999 129 152
56. E.F. Domino Nicotine induced behavioral locomotor sensitization Prog Neuro-Psychopharm Biol Psychiatry 25 2001 59 71
57. R.C. Pierce, and P.W. Kalivas A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants Brain Res Brain Res Rev 25 1997 192 216
58. P.W. Kalivas Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants Drug Alcohol Depend 37 1995 95 100
59. V. Deroche, M. Le Moal, and P.V. Piazza Cocaine self-administration increases the incentive motivational properties of the drug in rats Eur J Neurosci 11 1999 2731 2736
60. D.K. Miller, L.H. Wilkins, and M.T. Bardo Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism Psychopharmacology (Berl) 156 2001 469 476
61. M.R. Picciotto, B.J. Caldarone, and S.L. King Nicotinic receptors in the brain: links between molecular biology and behavior Neuropsychopharmacology 22 2000 451 465
62. A.R. Tapper, S.L. McKinney, and R. Nashmi Nicotine activation of alpha 4 receptors: sufficient for reward, tolerance, and sensitization Science 306 2004 1029 1032
63. P. Greengard The neurobiology of slow synaptic transmission Science 294 2001 1024 1030
64. G.F. Koob, P.P. Sanna, and F.E. Bloom Neuroscience of addiction Neuron 21 1998 467 476
65. J.D. Steketee Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants Brain Res Brain Res Rev 41 2003 203 228
66. S. Leonard, and D. Bertrand Neuronal nicotinic receptors: from structure to function Nicotine Tob Res 3 2001 203 223
67. G. Di Chiara Role of dopamine in the behavioural actions of nicotine related to addiction Eur J Pharmacol 393 2000 295 314
68. A. Schoffelmeer, T.J. De Vries, and G. Wardeh Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation J Neurosci 22 2002 3269 3276
69. H.L. Kimmel, I. Carroll, and M.J. Kuhar Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum J Pharmacol Exp Ther 304 2003 15 21
70. K.M. Kahlig, and A. Galli Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine Eur J Pharmacol 479 2003 153 158
71. C. Roubert, C. Spielewoy, and P. Soubrie Altered neurotensin mRNA expression in mice lacking the dopamine transporter Neuroscience 123 2004 537 546
72. A.A. Fienberg, N. Hiroi, and P.G. Mermelstein DARPP-32: regulator of the efficacy of dopaminergic neurotransmission Science 281 1998 838 842
73. V. Zachariou, M. Benoit-Marand, and P.B. Allen Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP-32 or inhibitor 1 Biol Psychiatry 1 2002 612 620
74. R. Carraway, and S.E. Leeman The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami J Biol Chem 248 1973 6854 6861
75. E.B. Binder, B. Kinkead, and M.J. Owens The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs Biol Psychiatry 50 2001 856 872
76. B. Kinkead, E.B. Binder, and C.B. Nemeroff Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry 46 1999 340 351
77. B.M. McMahon, M. Boules, and L. Warrington Neurotensin analogs. indications for use as potential antipsychotic compounds Life Sci 70 2002 1101 1119
78. P.W. Kalivas, C.B. Nemeroff, and A.J. Prange Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing Neuroscience 11 1984 919 930
79. G.N. Ervin, L.S. Birkemo, and C.B. Nemeroff Neurotensin blocks certain amphetamine-induced behaviours Nature 29 1981 73 76
80. P. Brun, M. Leonetti, and F. Sotty Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist J Neurochem 77 2001 1542 1552
81. C.B. Nemeroff Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry 15 1980 283 302
82. S.S. Wolf, T.M. Hyde, and R.C. Saunders Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects J Neural Transm 102 1995 55 65
83. R.P. Sharma, P.G. Janicak, and G. Bissette CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder Am J Psychiatry 154 1997 1019 1021
84. B. Kinkead, S. Shahid, and M.J. Owens Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain J Pharmacol Exp Ther 295 2000 67 73
85. F. Le, B. Cusack, and E. Richelson The neurotensin receptor: is there more than one subtype? Trends Pharmacol Sci 17 1996 1 3
86. J.P. Vincent, J. Mazella, and P. Kitabgi Neurotensin and neurotensin receptors Trends Pharmacol Sci 20 1999 302 309
87. G.R. Uhl, and S.H. Snyder Neurotensin receptor binding, regional and subcellular distributions favor transmitter role Eur J Pharmacol 41 1977 89 91
88. P. Kitabgi, R. Carraway, and J. Van Rietschoten Neurotensin: specific binding to synaptic membranes from rat brain Proc Natl Acad Sci U S A 74 1977 1846 1850
89. B.S. Slusher, A.E. Zacco, and J.A. Maslanski The cloned neurotensin receptor mediates cyclic GMP formation when coexpressed with nitric oxide synthase cDNA Mol Pharmacol 46 1994 115 121
90. M. Yamada, M. Yamada, and M.A. Watson Neurotensin stimulates cyclic AMP formation in CHO-rNTR-10 cells expressing the cloned rat neurotensin receptor Eur J Pharmacol 244 1993 99 101
91. M.A. Watson, M. Yamada, and M. Yamada The rat neurotensin receptor expressed in Chinese hamster ovary cells mediates the release of inositol phosphates J Neurochem 59 1992 1967 1970
92. C. Poinot-Chazel, M. Portier, and M. Bouaboula Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24 Biochem J 320 1996 145 151
93. K. Fuxe, W.T. O'Connor, and T. Antonelli Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum Proc Natl Acad Sci U S A 89 1992 5591 5595
94. 2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study J Neural Transm Gen Sect 102 1995 125 137
95. 2 dopamine receptors in rat striatal membranes Acta Physiol Scand 131 1987 625 626
96. J. Mazella, N. Zsurger, and V. Navarro The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor J Biol Chem 273 1998 26273 26276
97. P. Sarret, P. Krzywkowski, and L. Segal Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system J Comp Neurol 461 2003 483 505
98. A. Nykjaer, R. Lee, and K.K. Teng Sortilin is essential for proNGF-induced neuronal cell death Nature 427 2004 843 848
99. D. Gully, M. Canton, and R. Boigegrain Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor Proc Natl Acad Sci U S A 90 1993 65 69
100. D. Gully, B. Labeeuw, and R. Boigegrain Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist J Pharmacol Exp Ther 280 1997 802 812
101. B.A. Horger, J.R. Taylor, and J.D. Elsworth Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization Neuropsychopharmacology 11 1994 215 222
102. P.P. Rompre, and S. Perron Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization Neuropharmacology 39 2000 1880 1892
103. M. Boules, P. Fredrickson, and E. Richelson Current topics: brain penetrating neurotensin analog Life Sci 73 2003 2785 2792
104. A.H. Fauq, F. Hong, and B. Cusack Synthesis of (2S)-2-amino-3-(1H-4- indolyl)-propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides Tetrahedron Asymmetry 9 1998 4127 4134
105. B.M. Tyler-McMahon, and J.A. Stewart Highly potent neurotensin analog that causes hypothermia and antinociception Eur J Pharmacol 390 2000 107 111
106. B. Cusack, M. Boules, and B.M. Tyler Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol Brain Res 856 2000 48 54
107. M. Boules, L. Warrington, and A. Fauq A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity Eur J Pharmacol 426 2001 73 76
108. P. Fredrickson, M. Boules, and S. Yerbury Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats Eur J Pharmacol 458 2003 111 118
109. P. Fredrickson, M. Boules, and S. Yerbury Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization Brain Res 979 2003 245 248
110. E. Richelson, M. Boules, and P. Fredrickson Neurotensin agonists: possible drugs for treatment of psychostimulant abuse Life Sci 73 2003 679 690
111. W.E. Fantegrossi, M.C.H. Ko, and J.H. Woods Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys Pharmacol Biochem Behav 80 2005 341 349
112. 3H]SR 142948A, in the rat brain Eur J Pharmacol 343 1998 67 77
113. 2 receptor expressed in Chinese hamster ovary cells Eur J Pharmacol 360 1998 265 272